Abstract
We report the synthesis of new compounds 4-35 based on structural modifications of different moieties of previously described lead UCM-2550. The new nonpiperazine derivatives, representing second-generation agonists, were assessed for binding affinity, selectivity, and functional activity at the 5-HT 1A receptor (5-HT 1AR). Computational β 2-based homology models of the ligand-receptor complexes were used to explain the observed structure-affinity relationships. Selected candidates were also evaluated for their potential in vitro and in vivo neuroprotective properties. Interestingly, compound 26 (2-{6-[(3,4-dihydro-2H- chromen-2-ylmethyl)amino]hexyl}tetrahydro-1H-pyrrolo[1,2-c]imidazole-1,3(2H) -dione) has been characterized as a high-affinity and potent 5-HT 1AR agonist (K i = 5.9 nM, EC 50 = 21.8 nM) and exhibits neuroprotective effect in neurotoxicity assays in primary cell cultures from rat hippocampus and in the MCAO model of focal cerebral ischemia in rats. © 2011 American Chemical Society.
Cite
CITATION STYLE
Marco, I., Valhondo, M., Martín-Fontecha, M., Vázquez-Villa, H., Del Río, J., Planas, A., … López-Rodríguez, M. L. (2011). New serotonin 5-HT 1A receptor agonists with neuroprotective effect against ischemic cell damage. Journal of Medicinal Chemistry, 54(23), 7986–7999. https://doi.org/10.1021/jm2007886
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.